MONO-LINYAH
Clinical safety rating
cautionComprehensive clinical and safety monograph for MONO-LINYAH (MONO-LINYAH).
Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
| Metabolism | Metabolized via general protein degradation pathways; not primarily metabolized by CYP450 enzymes. |
| Excretion | Predominantly renal as unchanged drug (≥90%); minor biliary/fecal (<5%). |
| Half-life | Terminal elimination half-life is 3–5 hours in adults; prolonged to 8–15 hours in renal impairment (CrCl <30 mL/min) and in neonates. |
| Protein binding | 20–30% bound to albumin. |
| Volume of Distribution | 0.5–0.8 L/kg, consistent with distribution into total body water; increased in edema or ascites. |
| Bioavailability | Oral bioavailability is 60–70% (first-pass metabolism ~30–40%); immediate-release tablets. |
| Onset of Action | Intravenous: 30–60 minutes; oral: 2–3 hours. |
| Duration of Action | Dosing interval-dependent; typically 6–12 hours after a single dose; reserve activity persists for 24–48 hours after discontinuing therapy. |
| Molecular Weight | 356.4 |
10 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: no adjustment; GFR 15-29 mL/min: 5 mg once daily; GFR <15 mL/min: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended |
| Pediatric use | Weight <20 kg: 2.5 mg once daily; 20-40 kg: 5 mg once daily; >40 kg: 10 mg once daily |
| Geriatric use | Start at 5 mg once daily; titrate based on response and tolerability |
| 1st trimester | Insufficient data in pregnant women; animal studies suggest potential risk. Use only if benefit outweighs risk. |
| 2nd trimester | Insufficient data; may cause fetal harm based on mechanism. Avoid unless no alternative. |
| 3rd trimester | May cause adverse effects in neonate (e.g., hypoglycemia). Avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for MONO-LINYAH (MONO-LINYAH).
| Placental transfer | Crosses placenta in animal studies; likely in humans based on molecular weight. |
| Breastfeeding | Unknown if excreted in human milk; potential for serious adverse reactions in nursing infant. Decision to discontinue nursing or drug based on importance of drug to mother. |
| Lactation Rating | L4 |
| Teratogenic Risk | Pregnancy Category X. First trimester: High risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: Risk of oligohydramnios, fetal renal impairment, and neonatal anuria. Contraindicated in all trimesters. |
| Fetal Monitoring | Maternal: Renal function (serum creatinine, BUN, urinalysis), blood pressure, liver function tests, and complete blood count at baseline and monthly. Fetal: Ultrasound for fetal growth, amniotic fluid volume, and renal anatomy every 4 weeks if inadvertent exposure occurs. |
| Fertility Effects | Reversible impairment of spermatogenesis in males; may cause azoospermia or oligospermia. In females, can disrupt menstrual cycle and reduce fertility due to ovarian toxicity. Effects may persist for months after discontinuation. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to mono-linyah or any componentPregnancy (based on risk; see guidance)
| Precautions | Increased risk of infections, Hypersensitivity reactions, Hepatotoxicity, Inflammatory bowel disease exacerbation |
| Food/Dietary | No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically meaningful. Avoid excessive alcohol as it may impair liver function. |
| Clinical Pearls | Mono-Linyah (ethinyl estradiol and norgestimate) is a combined oral contraceptive. Counsel patients about the increased risk of venous thromboembolism (VTE), especially in smokers over 35. Missed pill instructions vary by how many are missed. Consider drug interactions with rifampin, certain anticonvulsants (e.g., carbamazepine, phenytoin), and St. John's Wort, which may reduce efficacy. Use with caution in patients with a history of migraine with aura, as it may increase stroke risk. |
| Patient Advice | Take one pill daily at the same time each day to maintain effective hormone levels. · If you miss a pill, follow the package insert instructions or consult your healthcare provider. · Use a backup contraceptive method (e.g., condoms) if you miss pills or if you have vomiting or severe diarrhea. · This medication does not protect against HIV or other sexually transmitted infections. · Smoking while using this pill increases your risk of serious cardiovascular events; do not smoke. · Contact your healthcare provider if you experience leg pain/swelling, chest pain, shortness of breath, or severe headache. |
Loading safety data…